Compare ADMA Biologics Inc (ADMA) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BIL | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Fixed Income |
52-Week High | $20.38 | $91.77 |
52-Week Low | $7.60 | $91.27 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.
The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
